Nonerosive reflux disease

In current clinical practice, many patients with symptomatic GERD are treated empirically with medications without prior endoscopy, ie, without knowledge of whether the patient has erosive or nonerosive reflux disease. Empiric treatment with proton pump inhibitors provides sustained symptomatic relief in 70-80% of patients, compared with 50-60% with H2 antagonists. Because of recent cost reductions, proton pump inhibitors are being used increasingly as first-line therapy for patients with symptomatic GERD. 

Fass R Erosive esophagitis and nonerosive reflux disease (NERD) Comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007 41 131. [PMID 17245209]... 

BE Barrett s esophagus ENRD endoscopy-negative reflux disease GERD gastroesophageal reflux disease LES lower esophageal sphincter NERD nonerosive reflux disease... 

Richter, J. E., Campbell, D. R., Kahrilas, P. J., Huang, B., and Eludas, C. (2000) Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch. Intern. Med. 160, 1803-1809. 

Proton pump inhibitors are the most effective agents for the treatment of nonerosive and erosive reflux disease, esophageal complications of reflux disease (peptic stricture or Barrett s esophagus), and extraesophageal manifestations of reflux disease. Once-daily dosing provides effective symptom relief and tissue healing in 85-90% of patients up to 15% of patients require twice-daily dosing. 

---